An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike protein domains are largely unknown. Here, we screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell
Egile Nagusiak: Liu, Yafei, Soh, Wai Tuck, Kishikawa, Jun-ichi, Hirose, Mika, Nakayama, Emi E., Li, Songling, Sasai, Miwa, Suzuki, Tatsuya, Tada, Asa, Arakawa, Akemi, Matsuoka, Sumiko, Akamatsu, Kanako, Matsuda, Makoto, Ono, Chikako, Torii, Shiho, Kishida, Kazuki, Jin, Hui, Nakai, Wataru, Arase, Noriko, Nakagawa, Atsushi, Matsumoto, Maki, Nakazaki, Yukoh, Shindo, Yasuhiro, Kohyama, Masako, Tomii, Keisuke, Ohmura, Koichiro, Ohshima, Shiro, Okamoto, Toru, Yamamoto, Masahiro, Nakagami, Hironori, Matsuura, Yoshiharu, Kato, Takayuki, Okada, Masato, Standley, Daron M., Shioda, Tatsuo, Arase, Hisashi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier Inc. 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8142859/
https://ncbi.nlm.nih.gov/pubmed/34139176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2021.05.032
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak